id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2969-0001,FDA,FDA-2022-N-2969,Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,Notice,Announcement,2022-12-14T05:00:00Z,2022,12,2022-12-14T05:00:00Z,,2022-12-14T15:11:12Z,2022-27022,0,0,090000648553630a